

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

## Olerup SSP<sup>®</sup> HLA-A low resolution

Product number:	101.401-48/12 – including <i>Taq</i> polymerase 101.401-48u/12u – without <i>Taq</i> polymerase
Lot number:	02N
Expiry date:	2014-April-01
Number of tests:	48 tests – Product No. 101.401-48/48u 12 tests – Product No. 101.401-12/12u
Number of wells per test:	31 +1
Storage - pre-aliquoted primers:	dark at -20°C
- PCR Master Mix:	-20°C
- Adhesive PCR seals	RT
- Product Insert	RT

**This Product Description is only valid for Lot No. 02N.**

### CHANGES COMPARED TO THE PREVIOUS OLERUP SSP<sup>®</sup> HLA-A LOW RESOLUTION LOT

Eight wells have been added to the HLA-A low kit, wells **25 to 32**.

The Lot-specific information for HLA A low resolution including and without *Taq* polymerase is now described in one common Product Insert.

The **HLA-A low resolution** specificity and interpretation tables have been updated for the HLA-A alleles described since the previous Olerup SSP<sup>®</sup> HLA-A low resolution lot was made (**Lot No. 94M**).

The primers of the wells detailed below have been exchanged, modified or added compared to the previous lot.

Well	5'-primer	3'-primer	rationale
1	Moved	Moved	Primer pair moved to well 26, for improved resolution of A*01 alleles.
2	Added	-	Increased yield of specific PCR product.
3	Moved	Moved	Primer pair moved to well 26, for improved resolution of A*03 alleles.
6	Modified	-	Increased yield of specific PCR product.
8	-	Added	Primer added for the A*25:15 allele.
9	Added	-	Primer added for the A*25:15 allele.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

**Lot No.: 02N****Lot-specific information**

12	Added	Added	Improved resolution of HLA-A*68 alleles.
13	-	Modified	Improved yield of specific PCR product.
15	Added	-	Primers added for the A*30:47 and 30:52 alleles.
24	Moved, added	Moved, added	Negative control moved to well 32, primer pair added for the A*66:12 allele
25	New	New	Improved resolution of the A19 group of alleles.
26	New	New	Primer pair from well 1, improved resolution of the A*43:01 allele.
27	New	New	Primer pair from well 1.
28	New	New	Improved resolution of A*03 alleles.
29	New	New	Improved resolution of A*26 alleles.
30	New	New	Improved resolution of A*66 alleles.
31	New	New	Improved resolution of A*34 alleles.
32	New	New	Negative control, from well 24.

Change in revision R01 compared to R00:

1. The HLA-A\*68:13 allele is amplified by primer mix 4. This has been corrected in the specificity and interpretation tables.

Change in revision R02 compared to R01:

1. The interpretation table has been corrected to include the A\*68:83 allele.

Change in revision R03 compared to R02:

1. A footnote has been added to the specificity table, stating that primer mix 9 may weakly amplify the A\*34 alleles.

Change in revision R04 compared to R03:

1. The HLA-A\*01:02 and 01:20 alleles are amplified by primer mix 25. This has been corrected in the Specificity and Interpretation Tables.

Changes in revision R05 compared to R04:

1. The HLA-A\*03:01:03, 03:09, 03:23:01, 03:89, 03:108, 11:06, 11:18, 24:28, 24:89, 26:03:01-26:03:02, 26:06, 26:07:02, 26:21, 26:30, 30:13, 30:16, 30:44, 30:46, 68:05, 68:15, 68:20 and 68:30 alleles are weakly amplified by primer mix 2. This has been corrected in the Specificity and Interpretation Tables.

2. Primer mix 17 does not amplify the HLA-A\*36:02 allele. This has been corrected in the Specificity and Interpretation Tables.

Change in revision R06 compared to R05:

1. In primer mix 5, the specific PCR product of 535 base pairs may be difficult to distinguish from the internal control band. A foot note has been added to the Specificity Table.

Change in revision R07 compared to R06:

1. Primer mix 30 amplifies the A\*32:26 allele. This has been corrected in the Specificity and Interpretation Tables.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

**Lot-specific information**

Well **32** contains Negative Control primer pairs, that will amplify more than 95% of the *Olerup SSP*<sup>®</sup> HLA Class I, DRB, DQB1 and DPB1 amplicons as well as an amplicon generated by a positive control primer pair.

PCR product sizes range from 75 to 430 base pairs.  
 The PCR product generated by the control primer pair is 430 base pairs.

Length of PCR product	105	200	105	80	75	80
<b>5'-primer<sup>1</sup></b>	<b>164</b>	<b>340</b>	<b>440</b>	<b>45</b>	<b>45</b>	<b>43</b>
	5'-CAC <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-TTA <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>	5'-Tgg <sup>3'</sup>
<b>3'-primer<sup>2</sup></b>	<b>231</b>	<b>2<sup>nd</sup> I</b>	<b>507</b>	<b>59</b>	<b>58</b>	<b>57</b>
	5'-TgC <sup>3'</sup>	5'-AAA <sup>3'</sup>	5'-TTg <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTC <sup>3'</sup>
<b>A*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>B*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>C*</b>	<b>+</b>	<b>+</b>	<b>+</b>			
<b>DRB1</b>				<b>+</b>	<b>+</b>	
<b>DRB3</b>				<b>+</b>	<b>+</b>	
<b>DRB5</b>				<b>+</b>		
<b>DQB1</b>					<b>+</b>	
<b>DPB1</b>						<b>+</b>

<sup>1</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>2</sup>The nucleotide position for HLA class I genes and the codon for HLA class II genes, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon or the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide and codon numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

## PRODUCT DESCRIPTION

### HLA-A low resolution

#### CONTENT

The primer set contains 5'- and 3'-primers for grouping the HLA-A\*01:01 to A\*80:02 alleles into the corresponding serological groups A1 to A80.

#### PLATE LAYOUT

Each test consists of 32 PCR reactions in a 32 well PCR plate. This lot is manufactured using white plastic trays.

1	2	3	4	5	6	7	8
9	10	11	12	13	14	15	16
17	18	19	20	21	22	23	24
25	26	27	28	29	30	31	32

Wells 1 to 31 – HLA-A low resolution primers.

Well 32 – Negative Control.

The 32 well PCR plate is marked with ‘HLA-A low’ in silver/gray ink.

Well No. 1 is marked with the Lot No. ‘02N’.

A faint row of numbers is seen between wells 1 and 2 or wells 7 and 8 of the PCR trays. These stem from the manufacture of the trays, and should be disregarded.

The PCR plates are covered with a PCR-compatible foil.

**Please note:** When removing each 32 well PCR plate, make sure that the remaining plates stay covered. Use a scalpel or a similar instrument to carefully cut the foil between the plates.

#### INTERPRETATION

Only HLA-A alleles will be amplified by the 32 wells of the HLA-A low resolution primer set except that primer mix 6 will amplify the B\*18:27 allele. Thus, the interpretation of HLA-A low resolution is only influenced by this HLA-B allele and not by other HLA Class I genes.

#### UNIQUELY IDENTIFIED ALLELES

All the HLA-A alleles, i.e. **A\*01:01 to A\*80:02**, recognized by the HLA Nomenclature Committee in July 2011<sup>1</sup> will be amplified by the primers in the HLA-A low resolution primer set. The HLA-A alleles will be grouped into their corresponding serological specificities<sup>2</sup>.

<sup>1</sup>HLA-A, HLA-B and HLA-C alleles listed on the IMGT/HLA web page 2011-July-14, release 3.5.0, [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla).

<sup>2</sup>The A\*23:14 and the A\*24:05 and 24:13:02 alleles will give rise to identical amplification patterns. These three alleles can be separated by the respective high resolution SSP primer sets.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

## SPECIFICITY TABLE

### HLA-A low resolution primer set

Specificities and sizes of the PCR products of the 31+1 primer mixes used for HLA-A low resolution SSP typing

Primer Mix	Size of spec. PCR product <sup>1</sup>	Size of control band <sup>2</sup>	HLA-A serology <sup>3</sup>	Amplified HLA-A alleles <sup>4,5,6</sup>
<b>1<sup>7,9</sup></b>	120 bp, 145 bp	<b>800 bp</b>	A1, A36	*01:01:01:01-01:01:31, 01:01:33-01:04N, 01:06-01:33, 01:35-01:68, 01:70-01:101, 36:01-36:05
<b>2<sup>8</sup></b>	210 bp, 255 bp, 365 bp, 415 bp	<b>800 bp</b>	A2,A19, A28, A203, A210, A3, A11, A9, A26, A30, A68	*02:01:01:01-02:01:15, 02:01:17-02:01:19, 02:01:21-02:22:02, 02:24:01-02:35:01, 02:35:03-02:47, 02:49-02:77, 02:78 <sup>w</sup> , 02:79:01-02:97:02, 02:99, 02:101:01-02:128, 02:130-02:323, 02:325-02:326, 03:01:03 <sup>w</sup> , 03:09 <sup>w</sup> , 03:23:01 <sup>w</sup> , 03:89 <sup>w</sup> , 03:108 <sup>w</sup> , 11:06 <sup>w</sup> , 11:18 <sup>w</sup> , 24:28 <sup>w</sup> , 24:89 <sup>w</sup> , 26:03:01-26:03:02 <sup>w</sup> , 26:06 <sup>w</sup> , 26:07:02 <sup>w</sup> , 26:21 <sup>w</sup> , 26:30 <sup>w</sup> , 30:13 <sup>w</sup> , 30:16 <sup>w</sup> , 30:44 <sup>w</sup> , 30:46 <sup>w</sup> , 68:05 <sup>w</sup> , 68:15 <sup>w</sup> , 68:20 <sup>w</sup> , 68:30 <sup>w</sup>
<b>3<sup>9</sup></b>	235 bp	1070 bp	A3,A32/A3, A36	*03:01:01:01-03:01:29, 03:01:31-03:04:02, 03:06-03:09, 03:11N-03:17, 03:19-03:39, 03:41, 03:43-03:74, 03:76-03:94, 03:96-03:97, 03:99-03:104, 03:106-03:121, 03:123-03:132, 32:04, 36:02
<b>4</b>	190 bp	<b>800 bp</b>	A1,A3,A11, A30, A36, A68	*01:01:01:01-01:01:22, 01:01:24-01:04N, 01:06-01:07, 01:09-01:11N, 01:13, 01:16N-01:18N, 01:20-01:29, 01:31N-01:33, 01:35-01:78, 01:80-01:98, 01:100-01:101, 02:78, 02:169, 03:12, 03:18, 03:88, 11:01:01-11:27, 11:29-11:106, 26:19, 30:08, 36:04, 68:13, 68:66
<b>5<sup>8,16</sup></b>	160 bp, 535 bp	<b>800 bp</b>	A3, A9, A23, A24, A2403, A31, A32	*01:95, 03:30, 23:01:01-23:46, 24:02:01:01-24:11N, 24:13:01-24:15, 24:17-24:64, 24:66-24:88, 24:90N-24:128, 24:130-24:182, 31:08, 32:05, 32:13
<b>6<sup>11</sup></b>	135 bp, 175 bp, 210 bp	<b>800 bp</b>	A9,A23, A24, A29, A80	*23:01:01-23:46, 24:05, 24:13:02, 24:24, 29:07, 31:29, 80:01-80:02, <b>B*18:27</b>

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

<b>7<sup>8</sup></b>	175 bp, 205 bp	1070 bp	A2, A9, A23, A24, A2403, A26, A33	*02:17:01 <sup>w</sup> -02:17:02 <sup>w</sup> , 23:14, 24:02:01:01-24:11N, 24:13:01-24:13:02, 24:17-24:50, 24:54-24:56, 24:58-24:63, 24:66-24:91, 24:93, 24:95-24:113, 24:115-24:137, 24:139-24:182, 26:16, 33:19, 68:45
<b>8<sup>8</sup></b>	165 bp, 200 bp	<b>800 bp</b>	A2/A28, A3, A10, A11, A25, A26, A32, A34, A66, A68, A69	*01:51, 02:55, 03:24, 03:50, 11:10, 25:01:01-25:16, 26:01:01-26:06, 26:08- 26:15, 26:17-26:18, 26:20-26:43:02, 26:45-26:63, 26:65-26:69, 29:28, 32:15, 33:51, 34:01:01-34:09, 66:01-66:16, 68:01:01:01-68:83, 69:01
<b>9<sup>7,15</sup></b>	75 bp	<b>800 bp</b>	A25, A32	*25:01:01-25:16, 32:01:01-32:02, 32:04, 32:06-32:36
<b>10<sup>7</sup></b>	85 bp	1070 bp	A10, A26, A33	*01:51, 01:83, 02:146, 26:01:01-26:02, 26:04, 26:07:01-26:18, 26:20, 26:22- 26:29, 26:31-26:43:02, 26:45-26:69, 33:13, 33:48
<b>11<sup>7,8</sup></b>	80 bp, 175 bp, 500 bp	1070 bp	A1, A9, A11, A26, A31, A34, A66	*01:13, 01:28, 03:63, 03:88, 11:01:01- 11:27, 11:29-11:106, 24:19, 24:44, 26:03:01-26:03:02, 26:06, 26:21, 31:03, 34:01:01-34:08, 66:01, 66:04-66:11, 66:13-66:15, 80:02
<b>12<sup>7</sup></b>	125 bp, 185 bp	<b>800 bp</b>	A3, A10, A25, A26, A31, A34, A43, A66	*02:309, 03:01:19, 11:11, 25:05-25:06, 26:09, 26:54, 31:03-31:04, 34:01:01- 34:09, 43:01, 66:02-66:03, 66:16
<b>13</b>	175 bp, 225 bp	1070 bp	A1, A2, A3, A10, A25, A26, A34, A43, A66	*01:13, 02:34-02:35:03, 02:56:01- 02:56:02, 02:62, 02:103, 02:135, 03:01:01:01-03:01:22, 03:01:24-03:07, 03:09-03:11N, 03:13-03:31, 03:33-03:35, 03:37-03:40, 03:42-03:56, 03:58, 03:60- 03:71, 03:73-03:87, 03:90-03:106, 03:109-03:110, 03:112-03:132, 25:01:01- 25:05, 25:07-25:16, 26:01:01-26:01:20, 26:01:22, 26:02 <sup>w</sup> , 26:03:01-26:03:02, 26:05-26:08, 26:10-26:33, 26:35- 26:43:02, 26:45-26:69, 30:55, 34:08, 43:01, 66:01, 66:04-66:15, 68:71, 74:13
<b>14<sup>7</sup></b>	100 bp, 200 bp, 240 bp	1070 bp	A26, A29, A31, A34	*02:237, 02:309, 03:95, 26:19, 26:22, 29:01:01:01-29:31, 31:03-31:04, 33:13, 33:48, 34:04, 66:09
<b>15<sup>7,8,10-12</sup></b>	90 bp, 135 bp, 205 bp	1070 bp	A1, A30	*01:13, 01:28, 03:43, 03:82, 30:01:01- 30:04:02, 30:06-30:20, 30:22-30:55, 31:35

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

<b>16</b>	240 bp, 370 bp, 395 bp	1070 bp	A31, A32	*02:237, 03:95, 29:14, 31:01:02-31:54, 32:05
<b>17</b>	140 bp, 180 bp	1070 bp	A32, A74	*01:95, 03:43, 03:82, 29:13, 31:35, 32:01:01-32:03, 32:05-32:36, 74:07
<b>18</b>	200 bp	1070 bp	A33, A68	*02:243, 33:01:01-33:01:06, 33:03:01-33:50, 68:29
<b>19</b>	160 bp, 200 bp	<b>800 bp</b>	A74	*29:19, 74:01-74:15
<b>20<sup>11</sup></b>	220 bp, 245 bp	<b>800 bp</b>	A2, A25, A28, A68	*02:34-02:35:03, 02:46, 02:48, 02:56:01-02:56:02, 02:62, 02:70, 02:78, 02:103, 02:129, 25:05, 26:54, 68:01:01:01-68:83
<b>21</b>	240 bp, 375 bp	<b>800 bp</b>	A2/A28, A26, A68, A69	*02:55, 02:243, 24:82, 26:22, 33:22, 66:09, 68:29, 69:01
<b>22<sup>7,13</sup></b>	85 bp, 240 bp	<b>800 bp</b>	A2, A36	*02:34-02:35:03, 02:46, 02:48, 02:56:01-02:56:02, 02:62, 02:70, 02:78, 02:103, 02:129, 36:01-36:05
<b>23<sup>7,11</sup></b>	70 bp, 160 bp, 240 bp, 495 bp	<b>800 bp</b>	A2/A28, A24/A3, A26, A36, A68, A80	*02:55, 03:41, 03:63, 03:75, 03:88, 24:18, 26:03:01-26:03:02, 26:05-26:06, 26:21, 26:30, 33:24, 36:02, 68:05, 68:15, 68:20, 80:01
<b>24</b>	360 bp		A3, A10, A26, A31, A66	*02:135, 02:309, 03:01:19, 25:13, 26:30, 26:65, 31:04, 34:09, 66:02-66:03, 66:12, 66:16
<b>25</b>	190 bp, 400 bp	1070 bp	A1, A29, A30, A31, A32, A33, A74	*01:02, 01:20, 29:01:01:01-29:29, 29:31, 30:01:01-30:04:02, 30:06-30:11:02, 30:13-30:17, 30:19-30:20, 30:22-30:30, 30:32-30:40, 30:42-30:54, 31:01:02-31:08, 31:10-31:27, 31:29-31:54, 32:01:01-32:23, 32:25-32:36, 33:01:01-33:01:06, 33:03:01-33:51, 74:01-74:15
<b>26</b>	195 bp, 225 bp	<b>800 bp</b>	A1, A36, A43	*01:01:01:01-01:02, 01:04N, 01:07-01:11N, 01:13, 01:16N-01:18N, 01:21-01:33, 01:35-01:52N, 01:54-01:62, 01:64, 01:67-01:72, 01:74-01:97, 01:99-01:101, 03:18, 11:11, 11:94, 36:04, 43:01
<b>27<sup>10</sup></b>	205 bp	1070 bp	A1, A3, A11, A30, A31, A32, A34	*01:12, 01:19, 01:21, 02:156, 03:01:01:01-03:01:01:03, 03:01:03-03:01:05, 03:01:07-03:01:13, 03:01:15-03:17, 03:19-03:49, 03:51-03:53, 03:55-03:63, 03:67-03:74, 03:76-03:94, 03:96-03:126, 03:128-03:132, 11:25, 11:31, 11:35, 11:60, 24:92, 30:04:01-30:04:02,

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

				30:06, 30:09, 30:17, 30:29, 30:46, 31:03-31:04, 32:04, 33:49, 34:02:01, 34:03-34:04, 34:07-34:09
<b>28<sup>7,10</sup></b>	100 bp	1070 bp	A2, A3, A9, A11, A23, A24, A28, A29, A30, A66, A68, A69	*02:34-02:35:03, 02:56:01-02:56:02, 02:62, 02:78, 02:103, 03:01:01:01-03:07, 03:09-03:28, 03:30-03:31, 03:33, 03:35, 03:37-03:40, 03:42-03:61, 03:64-03:87, 03:90-03:106, 03:109-03:132, 11:12, 23:13, 24:07, 24:24, 24:108, 24:112, 24:131, 29:01:01:01-29:18, 29:21-29:29, 29:31, 30:01:01-30:01:05, 30:08, 30:11:01-30:11:02, 30:14L-30:20, 30:23-30:26, 30:30, 30:35-30:43, 30:48-30:49, 30:52-30:55, 32:17, 34:09, 66:02, 66:12, 66:16, 68:01:01:01-68:02:04, 68:06-68:14, 68:16-68:19, 68:21:01-68:30, 68:32-68:39, 68:41-68:71, 68:73-68:83, 69:01, 74:13
<b>29<sup>12</sup></b>	260 bp	<b>800 bp</b>	A3, A11, A26, A30, A68, A74	*03:09, 03:108, 11:06, 11:18, 26:03:01-26:03:02, 26:06, 26:21, 26:30, 29:19, 30:13, 30:16, 30:44, 30:46, 33:24, 68:05, 68:15, 68:20, 74:06
<b>30<sup>14</sup></b>	180 bp	1070 bp	A25, A10, A26, A43, A66	*02:135, 25:01:01-25:05, 25:07-25:16, 26:01:01-26:01:20, 26:01:22-26:03:02, 26:05-26:08, 26:10-26:33, 26:35-26:43:02, 26:45-26:69, 32:26, 43:01, 66:01, 66:04-66:15
<b>31<sup>7</sup></b>	110 bp, 195 bp	1070 bp	A34	*34:01:01-34:02:02, 34:04-34:05, 34:07-34:09
<b>32<sup>17</sup></b>	-	-	-	<b>Negative control</b>

<sup>1</sup>Alleles are assigned by the presence of specific PCR product(s). However, the sizes of the specific PCR products may be helpful in the interpretation of HLA-A low resolution SSP typings. When the primers in a primer mix can give rise to specific PCR products of more than one length this is indicated if the size difference is 20 base pairs or more. Size differences shorter than 20 base pairs are not given. For high resolution SSP kits the respective lengths of the specific PCR product(s) of the alleles amplified by these primer mixes are given.

Nonspecific amplifications, i.e. a ladder or a smear of bands, may sometimes be seen. GC-rich primers have a higher tendency of giving rise to nonspecific amplifications than other primers.

PCR fragments longer than the control bands may sometimes be observed. Such bands should be disregarded and do not influence the interpretation of the SSP typings.

PCR fragments migrating faster than the control bands, but slower than a 400 bp fragment may be seen in some gel read-outs. Such bands can be disregarded and do not influence the interpretation of the SSP typings.

Some primers may give rise to primer oligomer artifacts. Sometimes this phenomenon is an inherent feature of the primer pair(s) of a primer mix. More often it is due to other factors such as too low amount of DNA in the PCR reactions, taking too long time in setting up the PCR reactions, working at elevated room temperature or using thermal cyclers that are not pre-heated.

<sup>2</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070



101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 02N****Lot-specific information**

base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-A low resolution typing.

In addition, wells number 2, 4 to 6, 8, 9, 12, 19 to 23, 26 and 29 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to allow kit identification.

In the presence of a specific amplification the intensity of the control band often decreases.

<sup>3</sup>The serological reactivity of all HLA-A alleles is not known. In this table we use the expert-assigned serological grouping in Tissue Antigens (2009) 73:95-170 and the serological grouping of the sequence-defined allele.

<sup>4</sup>Nucleotide sequence information is available for only exons 2 and 3 of many HLA Class I alleles and for only exon 2 of many HLA Class II alleles and not for other exons or for the introns of these alleles. We assume that unknown sequences in these exons and in the introns are conserved within loci and within allelic groups.

<sup>5</sup>The A\*23:14 and the A\*24:05 and 24:13:02 alleles will give rise to identical amplification patterns. These three alleles can be separated by the respective high resolution SSP primer sets.

<sup>6</sup>Primer mix 6 will amplify the B\*18:27 allele.

<sup>7</sup>Specific PCR fragments shorter than 125 base pairs have a lower intensity and are less sharp than longer PCR bands.

<sup>8</sup>The primer pairs in wells 2, 5, 7, 8, 11 and 15 will in many samples give rise to two or three HLA-specific PCR fragments.

<sup>9</sup>In primer mix 1, the positive control band may be slightly weaker than for other HLA-A low primer mixes.

<sup>10</sup>Primer mixes 15, 27 and 28 may yield less specific PCR product than the other primer mixes.

<sup>11</sup>Primer mixes 6, 15, 20 and 23 may have a tendency of primer dimer formation.

<sup>12</sup>Primer mixes 15 and 29 may have tendencies of unspecific amplifications.

<sup>13</sup>Primer mix 22 might faintly amplify most A\*11 alleles.

<sup>14</sup>Primer mix 30 may generate a false positive band of about 500 base pairs. This band should be disregarded when interpreting HLA-A low resolution typings.

<sup>15</sup>Primer mix 9 may weakly amplify the A\*34 alleles.

<sup>16</sup>In primer mix 5, the specific PCR product of 535 base pairs may be difficult to distinguish from the internal control band. The alleles giving rise to a product of this size are the following:

A\*01:95, 23:09, 24:02:06, 24:02:27, 24:08, 24:24, 24:29, 24:42, 24:67, 24:116, 24:137, 24:140, 24:145, 24:156, 24:171 and 32:13.

<sup>17</sup>Primer mix 32 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by control primer pairs. PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the control primer pair is 430 base pairs.

'w', might be weakly amplified.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: 02N

Lot-specific information

INTERPRETATION TABLE																
HLA-A low resolution SSP typing																
Amplification patterns of the A*01:01 to A*80:02 alleles																
	Well <sup>6,8</sup>															
	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
Length of spec.	120	210	235	190	160	135	175	165	75	85	80	125	175	100	90	240
PCR product(s)	145	255			535	175	205	200			175	185	225	200	135	370
		365				210					500			240	205	395
		415														
Length of int. pos. control <sup>1</sup>	800	800	1070	800	800	800	1070	800	800	1070	1070	800	1070	1070	1070	1070
5'-primer(s) <sup>2</sup>	98	48	363	98	144	176	98	98	266	257	301	103	98	98	203	41
	5'-CTT <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-ATA <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-gCC <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-CTA <sup>3'</sup>	5'-ACg <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-CCT <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-CAC <sup>3'</sup>	5'-gAA <sup>3'</sup>	5'-CTT <sup>3'</sup>
	103	78		413	317	368	368	102	266	259	302	423	423	238	362	355
	5'-CCT <sup>3'</sup>	5'-TCT <sup>3'</sup>		5'-CCg <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-gTT <sup>3'</sup>	5'-gTT <sup>3'</sup>	5'-ACA <sup>3'</sup>	5'-ACg <sup>3'</sup>	5'-CgA <sup>3'</sup>	5'-ggA <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-AgA <sup>3'</sup>	5'-ggT <sup>3'</sup>	5'-CCg <sup>3'</sup>
	123	106						413	266	261	385			355	363	
	5'-AgT <sup>3'</sup>	5'-CCA <sup>3'</sup>						5'-CCg <sup>3'</sup>	5'-Agg <sup>3'</sup>	5'-AAC <sup>3'</sup>	5'-ggC <sup>3'</sup>			5'-CCg <sup>3'</sup>	5'-ATA <sup>3'</sup>	
															363	
															369	
															5'-TAC <sup>3'</sup>	5'-ATA <sup>3'</sup>
															369	
3'-primer(s) <sup>3</sup>	203	240	555	256	265	270	259	259	302	299	341	257	282	257	299	238
	5'-TCT <sup>3'</sup>	5'-ggA <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-CTg <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-ACA <sup>3'</sup>	5'-gTT <sup>3'</sup>	5'-gTT <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-gAC <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CCT <sup>3'</sup>
		292	555	559	570	502	502	259			521	506	282	299	411	243
		5'-gTg <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-CTg <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-gTT <sup>3'</sup>			5'-ggg <sup>3'</sup>	5'-TgT <sup>3'</sup>	5'-gAC <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-TCA <sup>3'</sup>	5'-TCA <sup>3'</sup>
						538	539	538				559	559	418	526	265
						5'-CAG <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-CCA <sup>3'</sup>				5'-CTC <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-gTC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CCC <sup>3'</sup>
												559		555		555
												5'-CgT <sup>3'</sup>		5'-CCA <sup>3'</sup>		5'-CCA <sup>3'</sup>
Well No.	1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: 02N

Lot-specific information

INTERPRETATION TABLE																	
HLA-A low resolution SSP typing																	
Amplification patterns of the A*01:01 to A*80:02 alleles																	
Well <sup>6,8</sup>																	
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		
140	200	160	220	240	85	70	360	190	195	205	100	260	180	110	Neg. Control		Length of spec. PCR product(s)
180		200	245	375	240	160		400	225					195			
						240											
						495											
1070	1070	800	800	800	800	800	1070	1070	800	1070	1070	800	1070	1070			
180	98	180	78	28	78	176	341	41	103	363	282	74	418	270	Negative Control		5'-primer(s) <sup>2</sup>
5'-TTT <sup>3'</sup>	5'-CAC <sup>3'</sup>	5'-TTT <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-TCg <sup>3'</sup>	5'-TCT <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-ggC <sup>3'</sup>	5'-CTT <sup>3'</sup>	5'-CCT <sup>3'</sup>	5'-ATA <sup>3'</sup>	5'-Cag <sup>3'</sup>	5'-C <sup>3'</sup>	5'-Aga <sup>3'</sup>	5'-AAA <sup>3'</sup>			
203			106	261	527	261		123	363		282	78	423	363			
5'-gAA <sup>3'</sup>			5'-CCA <sup>3'</sup>	5'-AAC <sup>3'</sup>	5'-TgC <sup>3'</sup>	5'-AAC <sup>3'</sup>		5'-AgT <sup>3'</sup>	5'-ATA <sup>3'</sup>		5'-Cag <sup>3'</sup>	5'-TCC <sup>3'</sup>	5'-gCT <sup>3'</sup>	5'-ATA <sup>3'</sup>			
418			231			341											
5'-AgC <sup>3'</sup>			5'-CCT <sup>3'</sup>			5'-gga <sup>3'</sup>											
						355											
						5'-CCC <sup>3'</sup>											
290	256	299	265	97	265	292	418	270	257	527	341	292	559	341			
5'-CAA <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-ggT <sup>3'</sup>	5'-CCC <sup>3'</sup>	5'-gTg <sup>3'</sup>	5'-gTC <sup>3'</sup>	5'-ACA <sup>3'</sup>	5'-gCA <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-Cgg <sup>3'</sup>	5'-gTg <sup>3'</sup>	5'-CCg <sup>3'</sup>	5'-CgT <sup>3'</sup>			
317	256	299	282	355	282	292		270	545	527			559	517			
5'-ggA <sup>3'</sup>	5'-CTC <sup>3'</sup>	5'-CCA <sup>3'</sup>	5'-gAC <sup>3'</sup>	5'-gAC <sup>3'</sup>	5'-gAC <sup>3'</sup>	5'-gTT <sup>3'</sup>		5'-ACT <sup>3'</sup>	5'-Aga <sup>3'</sup>	5'-CCT <sup>3'</sup>			5'-CCg <sup>3'</sup>	5'-CgT <sup>3'</sup>			
555	259	341	282		282	299											
5'-CCA <sup>3'</sup>	5'-gTT <sup>3'</sup>	5'-CgT <sup>3'</sup>	5'-gAC <sup>3'</sup>		5'-gAC <sup>3'</sup>	5'-TCT <sup>3'</sup>											
			502		570	555											
			5'-CTT <sup>3'</sup>		5'-CAC <sup>3'</sup>	5'-CCA <sup>3'</sup>											
			506														
			5'-TgT <sup>3'</sup>														
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	Well No.	



101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*01:01:01:01-01:01:22, 01:01:24-01:01:31, 01:01:33- 01:01:43, 01:04N, 01:07, 01:09-01:11N, 01:16N- 01:18N, 01:22N-01:27N, 01:29, 01:31N-01:33, 01:35- 01:50, 01:52N, 01:54-01:62, 01:64, 01:67-01:68, 01:70- 01:72, 01:74-01:78, 01:80- 01:82, 01:84-01:94, 01:96- 01:97, 01:100-01:101	A1, Null, –	1			4												
*01:01:23, 01:08, 01:30, 01:79, 01:99	A1, –	1															
*01:01:32, 01:69	–				4												
*01:02	A1	1			4												
*01:03, 01:06, 01:53N, 01:63, 01:65-01:66, 01:73, 01:98	A1, Null, –	1			4												
*01:12, 01:19	A1, –	1															
*01:13	A1	1			4							11		13		15	
*01:14-01:15N	A1, Null	1															
*01:20	A1	1			4												
*01:21	A1	1			4												
*01:28	–	1			4							11				15	
*01:51	–	1			4				8			10					
*01:83	–	1			4							10					
*01:95	–	1			4	5											
*02:01:01:01-02:01:15, 02:01:17-02:01:19, 02:01:21- 02:16, 02:18-02:22:02, 02:24:01-02:33, 02:36-02:45, 02:47, 02:49-02:54, 02:57- 02:61, 02:63-02:69, 02:71- 02:77, 02:79:01-02:97:02, 02:99, 02:101:01-02:102, 02:104-02:128, 02:130- 02:134, 02:136-02:145, 02:147-02:155, 02:157- 02:168, 02:170-02:236, 02:238-02:242, 02:244- 02:308, 02:310-02:323, 02:325-02:326	A2, A19, Low A2, A203, A210, Null, –		2														
*02:17:01-02:17:02	A2		2						w								
*02:34-02:35:01, 02:35:03, 02:56:01-02:56:02, 02:62, 02:103	A2		2											13			
*02:35:02	A2													13			
*02:46, 02:70	A2		2														
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	Well No.
																ser <sup>5</sup>
																HLA-A allele <sup>4</sup>
									26							A1, Null, – *01:01:01:01-01:01:22, 01:01:24-01:01:31, 01:01:33- 01:01:43, 01:04N, 01:07, 01:09-01:11N, 01:16N- 01:18N, 01:22N-01:27N, 01:29, 01:31N-01:33, 01:35- 01:50, 01:52N, 01:54-01:62, 01:64, 01:67-01:68, 01:70- 01:72, 01:74-01:78, 01:80- 01:82, 01:84-01:94, 01:96- 01:97, 01:100-01:101
									26							A1, – *01:01:23, 01:08, 01:30, 01:79, 01:99
									26							– *01:01:32, 01:69
								25	26							A1 *01:02
																A1, Null, – *01:03, 01:06, 01:53N, 01:63, 01:65-01:66, 01:73, 01:98
											27					A1, – *01:12, 01:19
											26					A1 *01:13
																A1, Null *01:14-01:15N
								25								A1 *01:20
									26	27						A1 *01:21
									26							– *01:28
									26							– *01:51
									26							– *01:83
17									26							– *01:95
																Negative Control
																A2, A19, Low A2, A203, A210, Null, – *02:01:01:01-02:01:15, 02:01:17-02:01:19, 02:01:21- 02:16, 02:18-02:22:02, 02:24:01-02:33, 02:36-02:45, 02:47, 02:49-02:54, 02:57- 02:61, 02:63-02:69, 02:71- 02:77, 02:79:01-02:97:02, 02:99, 02:101:01-02:102, 02:104-02:128, 02:130- 02:134, 02:136-02:145, 02:147-02:155, 02:157- 02:168, 02:170-02:236, 02:238-02:242, 02:244- 02:308, 02:310-02:323, 02:325-02:326
																A2 *02:17:01-02:17:02
			20		22						28					A2 *02:34-02:35:01, 02:35:03, 02:56:01-02:56:02, 02:62, 02:103
			20		22						28					A2 *02:35:02
			20		22											A2 *02:46, 02:70
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	Well No.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*02:48, 02:129	A2, –																
*02:55	A2, A28		2						8								
*02:78	–		w		4												
*02:135	–		2											13			
*02:146	–		2								10						
*02:156	–		2														
*02:169	–		2		4												
*02:237	–		2												14		16
*02:243	–		2														
*02:309	–		2										12		14		
*03:01:01:01-03:01:01:03, 03:01:04-03:01:05, 03:01:07- 03:01:13, 03:01:15-03:01:18, 03:01:20-03:01:22, 03:01:24- 03:01:29, 03:01:31-03:04:02, 03:06-03:07, 03:11N, 03:13- 03:17, 03:19-03:22:02, 03:23:02, 03:25-03:28, 03:31, 03:33, 03:35, 03:37-03:39, 03:44-03:49, 03:51-03:53, 03:55-03:56, 03:58, 03:60- 03:61, 03:67-03:71, 03:73- 03:74, 03:76-03:81, 03:83- 03:87, 03:90-03:94, 03:96- 03:97, 03:99-03:104, 03:106, 03:109-03:110, 03:112- 03:121, 03:123-03:126, 03:128-03:132	A3, Null, –			3										13			
*03:01:02, 03:01:06, 03:01:14, 03:54, 03:64-03:66, 03:127	A3, –			3										13			
*03:01:03, 03:23:01	A3		w	3										13			
*03:01:19	–			3								12		13			
*03:01:23, 03:57, 03:59, 03:72, 03:111	–			3													
*03:01:30, 03:05, 03:10, 03:40, 03:42, 03:98, 03:105, 03:122	A3, –													13			
*03:08, 03:32, 03:36N, 03:107	A3, Null, –			3													
*03:09	A3		w	3										13			
*03:12	A3			3	4												
*03:18	–				4									13			
*03:24	A3			3					8					13			
*03:29, 03:34, 03:62	A3, –			3										13			
*03:30	A3			3		5								13			
*03:41	–			3													
*03:43, 03:82	–			3										13		15	
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.	
																ser <sup>5</sup>	HLA-A allele <sup>4</sup>	
			20		22											A2, -	*02:48, 02:129	
				21		23										A2, A28	*02:55	
			20		22						28					-	*02:78	
							24						30			-	*02:135	
											27					-	*02:146	
																-	*02:156	
																-	*02:169	
																-	*02:237	
	18			21												-	*02:243	
							24									-	*02:309	
											27	28				Negative Control	*03:01:01:01-03:01:01:03, 03:01:04-03:01:05, 03:01:07- 03:01:13, 03:01:15-03:01:18, 03:01:20-03:01:22, 03:01:24- 03:01:29, 03:01:31-03:04:02, 03:06-03:07, 03:11N, 03:13- 03:17, 03:19-03:22:02, 03:23:02, 03:25-03:28, 03:31, 03:33, 03:35, 03:37-03:39, 03:44-03:49, 03:51-03:53, 03:55-03:56, 03:58, 03:60- 03:61, 03:67-03:71, 03:73- 03:74, 03:76-03:81, 03:83- 03:87, 03:90-03:94, 03:96- 03:97, 03:99-03:104, 03:106, 03:109-03:110, 03:112- 03:121, 03:123-03:126, 03:128-03:132	
											28						A3, -	*03:01:02, 03:01:06, 03:01:14, 03:54, 03:64-03:66, 03:127
										27	28						A3	*03:01:03, 03:23:01
							24			27	28						-	*03:01:19
										27	28						-	*03:01:23, 03:57, 03:59, 03:72, 03:111
										27	28						A3, -	*03:01:30, 03:05, 03:10, 03:40, 03:42, 03:98, 03:105, 03:122
										27							A3, Null, -	*03:08, 03:32, 03:36N, 03:107
										27	28	29					A3	*03:09
										27	28						A3	*03:12
									26		28						-	*03:18
										27	28						A3	*03:24
										27							A3, -	*03:29, 03:34, 03:62
										27	28						A3	*03:30
						23				27							-	*03:41
17										27	28						-	*03:43, 03:82
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.	

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*03:50	-			3					8					13			
*03:63	-			3								11		13			
*03:75	-													13			
*03:88	-			3	4							11					
*03:89	-		w	3													
*03:95	-													13	14		16
*03:108	-		w	3													
*11:01:01-11:05, 11:07-11:09, 11:13-11:17, 11:19-11:24:02, 11:26-11:27, 11:29-11:30, 11:32-11:34, 11:36-11:59, 11:61-11:93, 11:95-11:106	A11, Null, -				4							11					
*11:06, 11:18	A11, -		w		4							11					
*11:10	A11				4				8			11					
*11:11	-				4							11	12				
*11:12	A11				4							11					
*11:25, 11:31, 11:35, 11:60	A11, -				4							11					
*11:94	-				4							11					
*23:01:01-23:12, 23:15-23:46	A23, Null, -					5	6										
*23:13	A23					5	6										
*23:14, 24:05, 24:13:02 <sup>7</sup>	A23, A9, A24					5	6	7									
*24:02:01:01-24:04, 24:06, 24:08-24:11N, 24:13:01, 24:17, 24:20-24:23, 24:25-24:27, 24:29-24:43, 24:45N-24:50, 24:54-24:56, 24:58-24:63, 24:66-24:81, 24:83N-24:88, 24:90N-24:91, 24:93, 24:95-24:107, 24:109-24:111, 24:113, 24:115-24:128, 24:130, 24:132N-24:137, 24:139-24:182	A24, Low A24, A2403, A9, Null, -					5		7									
*24:07, 24:108, 24:112, 24:131	A24, -					5		7									
*24:14-24:15, 24:51-24:53, 24:57, 24:64, 24:94, 24:114, 24:138	A24, -					5											
*24:18	A24, A3					5		7									
*24:19, 24:44	A9					5		7				11					
*24:24	A9					5	6	7									
*24:28	A9		w			5		7									
*24:82	-					5		7									
*24:89	-		w					7									
*24:129	-							7									
*24:92	-					5											
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16



101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32	ser <sup>5</sup>	Well No. HLA-A allele <sup>4</sup>
											28					-	*03:50
						23				27						-	*03:63
						23					28					-	*03:75
						23				27						-	*03:88
										27						-	*03:89
											28					-	*03:95
										27		29				-	*03:108
																A11, Null, -	*11:01:01-11:05, 11:07- 11:09, 11:13-11:17, 11:19- 11:24:02, 11:26-11:27, 11:29- 11:30, 11:32-11:34, 11:36- 11:59, 11:61-11:93, 11:95- 11:106
												29				A11, -	*11:06, 11:18
																A11	*11:10
									26							-	*11:11
											28					A11	*11:12
										27						A11, -	*11:25, 11:31, 11:35, 11:60
									26							-	*11:94
																A23, Null, -	*23:01:01-23:12, 23:15-23:46
											28					A23	*23:13
																A23, A9, A24	*23:14, 24:05, 24:13:02 <sup>7</sup>
																A24, Low A24, A2403, A9, Null, -	*24:02:01:01-24:04, 24:06, 24:08-24:11N, 24:13:01, 24:17, 24:20-24:23, 24:25- 24:27, 24:29-24:43, 24:45N- 24:50, 24:54-24:56, 24:58- 24:63, 24:66-24:81, 24:83N- 24:88, 24:90N-24:91, 24:93, 24:95-24:107, 24:109- 24:111, 24:113, 24:115- 24:128, 24:130, 24:132N- 24:137, 24:139-24:182
											28					A24, -	*24:07, 24:108, 24:112, 24:131
																A24, -	*24:14-24:15, 24:51-24:53, 24:57, 24:64, 24:94, 24:114, 24:138
						23										A24, A3	*24:18
											28					A9	*24:19, 24:44
																A9	*24:24
																A9	*24:28
				21												-	*24:82
																-	*24:89
																-	*24:129
										27						-	*24:92
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.

Negative Control



101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*25:01:01-25:04, 25:07-25:12N, 25:14-25:16	A25, – Null								8	9				13			
*25:05	A25								8	9			12	13			
*25:06	A25								8	9			12				
*25:13	–								8	9				13			
*26:01:01-26:01:20, 26:01:22, 26:08, 26:10-26:15, 26:17-26:18, 26:20, 26:23-26:29, 26:31-26:33, 26:35-26:43:02, 26:45-26:53, 26:55-26:63, 26:66-26:69	A26, A10, Null, –								8		10			13			
*26:01:21, 26:04, 26:34	A26, –								8		10						
*26:02	A26								8		10			w			
*26:03:01-26:03:02	A26		w						8			11		13			
*26:06, 26:21	A26, –		w						8			11		13			
*26:05	A26								8					13			
*26:07:01, 26:64	A26, –										10			13			
*26:07:02	–		w								10			13			
*26:09	A26								8		10		12				
*26:16	A26							7			10			13			
*26:19	–				4									13	14		
*26:22	A26								8		10			13	14		
*26:30	A26		w						8					13			
*26:54	–								8		10		12	13			
*26:65	–								8		10			13			
*29:01:01-29:06, 29:08N-29:12, 29:15-29:18, 29:21-29:27, 29:29, 29:31	A29, Null, –														14		
*29:07	A29						6								14		
*29:13	–														14		
*29:14	–														14		16
*29:19	–														14		
*29:20	–														14		
*29:28	–								8						14		
*29:30	–														14		
*30:01:01-30:01:05, 30:11:01-30:11:02, 30:14L-30:15, 30:19-30:20, 30:23-30:26, 30:30, 30:35-30:40, 30:42-30:43, 30:48-30:49, 30:52-30:54	A30, –																15
*30:02:01-30:03, 30:07, 30:10, 30:22, 30:27N-30:28, 30:32-30:34, 30:45, 30:47, 30:50-30:51	A30, Null, –																15
*30:04:01-30:04:02, 30:06, 30:09, 30:29	A30, –																15
*30:12, 30:31	A30, –																15
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.
																ser <sup>5</sup>	HLA-A allele <sup>4</sup>
			20										30			A25, – Null	*25:01:01-25:04, 25:07-25:12N, 25:14-25:16
													30			A25	*25:05
							24						30			A25	*25:06
																–	*25:13
													30			A26, – A10, Null, –	*26:01:01-26:01:20, 26:01:22, 26:08, 26:10-26:15, 26:17-26:18, 26:20, 26:23-26:29, 26:31-26:33, 26:35-26:43:02, 26:45-26:53, 26:55-26:63, 26:66-26:69
														30		A26, –	*26:01:21, 26:04, 26:34
														30		A26	*26:02
						23						29	30			A26	*26:03:01-26:03:02
						23						29	30			A26, –	*26:06, 26:21
						23							30			A26	*26:05
													30			A26, –	*26:07:01, 26:64
													30			–	*26:07:02
														30		A26	*26:09
														30		A26	*26:16
														30		–	*26:19
				21										30		A26	*26:22
						23	24					29	30			A26	*26:30
			20											30		–	*26:54
							24							30		–	*26:65
								25			28					A29, Null, –	*29:01:01:01-29:06, 29:08N-29:12, 29:15-29:18, 29:21-29:27, 29:29, 29:31
								25			28					A29	*29:07
17								25			28					–	*29:13
								25			28					–	*29:14
		19						25				29				–	*29:19
								25								–	*29:20
								25			28					–	*29:28
																–	*29:30
								25			28					A30, –	*30:01:01-30:01:05, 30:11:01-30:11:02, 30:14L-30:15, 30:19-30:20, 30:23-30:26, 30:30, 30:35-30:40, 30:42-30:43, 30:48-30:49, 30:52-30:54
								25								A30, Null, –	*30:02:01-30:03, 30:07, 30:10, 30:22, 30:27N-30:28, 30:32-30:34, 30:45, 30:47, 30:50-30:51
								25		27						A30, –	*30:04:01-30:04:02, 30:06, 30:09, 30:29
																A30, –	*30:12, 30:31
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.

Negative Control

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

## Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*30:12, 30:31	A30, –																15
*30:13, 30:44	A30, –		w														15
*30:16	A30		w														15
*30:17	A30																15
*30:18, 30:41	A30, –																15
*30:46	–		w														15
*30:55	–													13			15
*31:01:02-31:02, 31:05-31:07, 31:10-31:27, 31:30-31:34, 31:36-31:54	A31, Null, –																16
*31:03	A31											11	12		14		16
*31:04	A31												12		14		16
*31:08	A31, A24					5											16
*31:09, 31:28	A31, –																16
*31:29	–						6										16
*31:35	–															15	16
*32:01:01-32:02, 32:06-32:12, 32:14, 32:16, 32:18-32:23, 32:25, 32:27-32:36	A32, –, Null									9							
*32:03	A32																
*32:04	A32, A3			3						9							
*32:05	A32					5											16
*32:13	A32					5				9							
*32:15	A32								8	9							
*32:17	–									9							
*32:24	–									9							
*32:26	–									9							
*33:01:01-33:01:06, 33:03:01-33:12, 33:14-33:18, 33:20-33:21, 33:23, 33:25-33:47, 33:50	A33, –																
*33:13, 33:48	–										10				14		
*33:19	–							7									
*33:22	–																
*33:24	–																
*33:49	–																
*33:51	–								8								
*34:01:01-34:01:02, 34:02:02, 34:05	A34, –								8			11	12				
*34:02:01, 34:07	A34								8			11	12				
*34:03	A34								8			11	12				
*34:04	A34								8			11	12		14		
*34:06	A10								8			11	12				
*34:08	A34								8			11	12	13			
*34:09	–								8				12				
*36:01, 36:03, 36:05	A36, –	1															
*36:02	A36	1		3													
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.
																ser <sup>5</sup>	HLA-A allele <sup>4</sup>
								25				29				A30, –	*30:12, 30:31
								25			28	29				A30, –	*30:13, 30:44
								25		27	28					A30	*30:16
								25			28					A30	*30:17
											28					A30, –	*30:18, 30:41
								25		27		29				–	*30:46
											28					–	*30:55
								25								A31, Null, –	*31:01:02-31:02, 31:05-31:07, 31:10-31:27, 31:30-31:34, 31:36-31:54
								25		27						A31	*31:03
						24		25		27						A31	*31:04
								25								A31, A24	*31:08
																A31, –	*31:09, 31:28
								25								–	*31:29
17								25								–	*31:35
								25								A32, –, Null	*32:01:01-32:02, 32:06-32:12, 32:14, 32:16, 32:18-32:23, 32:25, 32:27-32:36
17								25								A32	*32:03
								25		27						A32, A3	*32:04
17								25								A32	*32:05
17								25								A32	*32:13
17								25								A32	*32:15
17								25			28					–	*32:17
17								25								–	*32:24
17								25					30			–	*32:26
	18							25								A33, –	*33:01:01-33:01:06, 33:03:01-33:12, 33:14-33:18, 33:20-33:21, 33:23, 33:25-33:47, 33:50
	18							25								–	*33:13, 33:48
	18							25								–	*33:19
	18			21				25								–	*33:22
	18					23		25			29					–	*33:24
	18							25		27						–	*33:49
								25								–	*33:51
														31		A34, –	*34:01:01-34:01:02, 34:02:02, 34:05
										27				31		A34	*34:02:01, 34:07
										27				31		A34	*34:03
										27				31		A34	*34:04
										27				31		A10	*34:06
										27				31		A34	*34:08
							24			27	28			31		–	*34:09
					22											A36, –	*36:01, 36:03, 36:05
					22	23										A36	*36:02
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.

Negative Control

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
HLA-A allele <sup>4</sup>	ser <sup>5</sup>																
*36:04	A36	1			4												
*43:01	A43												12	13			
*66:01, 66:04-66:08, 66:10-66:11, 66:13-66:15	A66, A26, –								8			11		13			
*66:02, 66:16	A66, –								8				12				
*66:03	A10								8				12				
*66:09	–								8			11		13	14		
*66:12	–								8					13			
*68:01:01:01-68:02:04, 68:06-68:12, 68:14, 68:16-68:19, 68:21:01-68:28, 68:32-68:39, 68:41-68:44, 68:46-68:65, 68:67-68:70, 68:73-68:83	A68, A28, Null, –								8								
*68:03:01-68:04, 68:31, 68:40, 68:72	A68, –								8								
*68:05, 68:15, 68:20	A68		w						8								
*68:13, 68:66	A68				4				8								
*68:29	A68								8								
*68:30	A68								8								
*68:45	–							7	8								
*68:71	–								8					13			
*69:01	A69								8								
*74:01-74:05, 74:08-74:12N, 74:14N-74:15	A74, Null, –																
*74:06	A74																
*74:07	A74																
*74:13	–													13			
*80:01	A80								6								
*80:02	–								6			11					
<i>B*18:27</i>	–								6								
Well No.		1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16

<sup>1</sup>The internal positive control primer pairs amplify segments of the human growth hormone gene. The two different control primer pairs give rise to either an internal positive control band of 1070 base pairs, for most wells, or a band of 800 base pairs, for some wells.

Well number 1 contains the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to help in the correct orientation of the HLA-A low resolution SSP typing.

In addition, wells number 2, 4 to 6, 8, 9, 12, 19 to 23, 26 and 29 contain the primer pair giving rise to the shorter, 800 bp, internal positive control band in order to allow kit identification.

<sup>2</sup>The nucleotide position, in the 1<sup>st</sup>, 2<sup>nd</sup> or 3<sup>rd</sup> exon or in the 2<sup>nd</sup> intron, matching the specificity-determining 3'-end of the primer is given. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

<sup>3</sup>The nucleotide position, in the 2<sup>nd</sup> or 3<sup>rd</sup> exon, matching the specificity-determining 3'-end of the primer is given in the anti-sense direction. Nucleotide numbering as on the [www.ebi.ac.uk/imgt/hla](http://www.ebi.ac.uk/imgt/hla) web site. The sequence of the 3 terminal nucleotides of the primer is given.

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.
																ser <sup>5</sup>	HLA-A allele <sup>4</sup>
				22					26							A36	*36:04
									26				30			A43	*43:01
													30			A66, A26, –	*66:01, 66:04-66:08, 66:10-66:11, 66:13-66:15
							24				28					A66, –	*66:02, 66:16
							24									A10	*66:03
				21									30			–	*66:09
							24				28		30			–	*66:12
			20								28					A68, A28, Null, –	*68:01:01:01-68:02:04, 68:06-68:12, 68:14, 68:16-68:19, 68:21:01-68:28, 68:32-68:39, 68:41-68:44, 68:46-68:65, 68:67-68:70, 68:73-68:83
			20													A68, –	*68:03:01-68:04, 68:31, 68:40, 68:72
			20			23						29				A68	*68:05, 68:15, 68:20
			20								28					A68	*68:13, 68:66
	18		20	21							28					A68	*68:29
			20								28					A68	*68:30
			20								28					–	*68:45
			20								28					–	*68:71
				21							28					A69	*69:01
		19						25								A74, Null, –	*74:01-74:05, 74:08-74:12N, 74:14N-74:15
		19						25				29				A74	*74:06
17		19						25								A74	*74:07
		19						25			28					–	*74:13
						23										A80	*80:01
																–	*80:02
																–	<i>B*18:27</i>
17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	32		Well No.

<sup>4</sup>The sequence of the A\*0105N has been shown to be identical to A\*01:04N.  
 The A\*01:34N allele has been renamed to A\* 01:01:38L.  
 The A\*020116 allele has been renamed to A\*02:134.  
 The A\*020120 allele has been renamed to A\*02:01:18.  
 The sequence of the A\*0223 allele has been shown to be identical to A\*02:22:01.  
 The sequence of the A\*0298 allele has been shown to be identical to A\*02:96.  
 The A\*02:100 allele has never been assigned.  
 The A\*1128 allele has been renamed to A\*11:15:02.  
 The A\*11:53 allele has been shown to be identical to corrected sequence of A\*11:02:01.  
 The sequence of the A\*2401 allele has been shown to be in error.  
 The sequence of the A\*2412 allele has been shown to be identical to A\*24:08.  
 The A\*2416 allele has been renamed to A\*31:08.  
 The A\*2465 allele has been renamed to A\*24:13:02.  
 The A\*26:44 allele has been renamed to A\*26:43:02.  
 The sequence of the A\*3005 allele has been shown to be identical to A\*30:04.  
 The A\*3021 allele has been renamed to A\*30:11:02.  
 The sequence of the A\*31011 allele has been shown to be identical to A\*31:01:02.

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

**Lot No.: 02N****Lot-specific information**

The sequence of the A\*3302 allele has been shown to be identical to A\*33:03:01.

<sup>5</sup>The serological reactivity of all HLA-A alleles is not known. In this table we use the expert-assigned serological grouping in Tissue Antigens (2009) 73:95-170 and the serological grouping of the sequence-defined allele.

<sup>6</sup>The primer pairs in wells 2, 5, 7, 8, 11 and 15 will in many samples give rise to two or three HLA-specific PCR fragments.

<sup>7</sup>The A\*23:14 and the A\*24:05 and 24:13:02 alleles will give rise to identical amplification patterns. These four alleles can be separated by the respective high resolution SSP primer sets.

<sup>8</sup>Primer mix 32 contains a negative control, which will amplify more than 95% of HLA amplicons as well as the amplicons generated by control primer pairs. PCR product sizes range from 75 to 200 base pairs. The PCR product generated by the control primer pair is 430 base pairs.

‘w’, may be weakly amplified.



101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

CELL LINE VALIDATION SHEET																				
HLA-A low resolution primer set																				
				Lot No.:	Well															
					1	2	3	4	5	6	7	8	9	10	11	12	13	14	15	16
					201191801	201191802	201191803	201191804	201191805	201191806	201191807	201191808	201191809	201191810	201191811	201191812	201191813	201191814	201191815	201191816
	IHCW cell line	A*	A*																	
1	9001 SA	*24:02			-	-	-	-	+	-	+	-	-	-	-	-	-	-		
2	9280 LK707	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
3	9011 E4181324	*01:01			+	-	-	+	-	-	-	-	-	-	-	-	-	-		
4	9275 GU373	*30:01			-	-	-	-	-	-	-	-	-	-	-	-	+	-		
5	9009 KAS011	*01:01			+	-	-	+	-	-	-	-	-	-	-	-	-	-		
6	9353 SM	*02:01	*26:03		-	+	-	-	-	-	-	+	-	-	+	-	-	-		
7	9020 QBL	*26:01			-	-	-	-	-	-	-	+	-	+	-	+	-	-		
8	9025 DEU	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+		
9	9026 YAR	*26:01			-	-	-	-	-	-	-	+	-	+	-	-	-	-		
10	9107 LKT3	*24:02			-	-	-	-	+	-	+	-	-	-	-	-	-	-		
11	9051 PITOUT	*29:02			-	-	-	-	-	-	-	-	-	-	-	+	-	-		
12	9052 DBB	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
13	9004 JESTHOM	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
14	9071 OLGA	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+		
15	9075 DKB	*24:02			-	-	-	-	+	-	+	-	-	-	-	-	-	-		
16	9037 SWEIG007	*29:02			-	-	-	-	-	-	-	-	-	-	-	+	-	-		
17	9282 CTM3953540	*03:01	*80:01		-	-	+	-	-	+	-	-	-	-	+	-	-	-		
18	9257 32367	*33:03	*74:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-		
19	9038 BM16	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
20	9059 SLE005	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
21	9064 AMALA	*02:17			-	+	-	-	-	-	W	-	-	-	-	-	-	-		
22	9056 KOSE	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
23	9124 IHL	*02:01	*34:01		-	+	-	-	-	-	+	-	-	+	+	-	-	-		
24	9035 JBUSH	*32:01			-	-	-	-	-	-	-	+	-	-	-	-	-	-		
25	9049 IBW9	*33:01			-	-	-	-	-	-	-	-	-	-	-	-	-	-		
26	9285 WT49	*02:05			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
27	9191 CH1007	*24:10	*29:01		-	-	-	-	+	-	+	-	-	-	-	+	-	-		
28	9320 BEL5GB	*02:01	*29:02		-	+	-	-	-	-	-	-	-	-	-	+	-	-		
29	9050 MOU	*29:02			-	-	-	-	-	-	-	-	-	-	-	+	-	-		
30	9021 RSH	*30:01	*68:02		-	-	-	-	-	-	-	+	-	-	-	-	+	-		
31	9019 DUCAF	*30:02			-	-	-	-	-	-	-	-	-	-	-	-	+	-		
32	9297 HAG	*02:01			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
33	9098 MT14B	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+		
34	9104 DHIF	*31:01			-	-	-	-	-	-	-	-	-	-	-	-	-	+		
35	9302 SSTO	*32:01			-	-	-	-	-	-	-	+	-	-	-	-	-	-		
36	9024 KT17	*02:06	*11:01		-	+	-	+	-	-	-	-	-	+	-	-	-	-		
37	9065 HHKB	*03:01			-	-	+	-	-	-	-	-	-	-	+	-	-	-		
38	9099 LZL	*02:17			-	+	-	-	-	-	W	-	-	-	-	-	-	-		
39	9315 CML	*01:01	*03:01		+	-	+	+	-	-	-	-	-	-	+	-	-	-		
40	9134 WHONP199	*02:07	*30:01		-	+	-	-	-	-	-	-	-	-	-	-	+	-		
41	9055 H0301	*03:01			-	-	+	-	-	-	-	-	-	-	+	-	-	-		
42	9066 TAB089	*02:07			-	+	-	-	-	-	-	-	-	-	-	-	-	-		
43	9076 T7526	*02:06	*02:07		-	+	-	-	-	-	-	-	-	-	-	-	-	-		
44	9057 TEM	*66:01			-	-	-	-	-	-	-	+	-	-	+	-	-	-		
45	9239 SHJO	*23:01	*24:02		-	-	-	-	+	+	+	-	-	-	-	-	-	-		
46	9013 SCHU	*03:01			-	-	+	-	-	-	-	-	-	-	+	-	-	-		
47	9045 TUBO	*02:16	*03:01		-	+	+	-	-	-	-	-	-	-	+	-	-	-		
48	9303 TER-ND	*02:01	*11:01		-	+	-	+	-	-	-	-	-	+	-	-	-	-		

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

CELL LINE VALIDATION SHEET																			
HLA-A low resolution primer set																			
				Well															
				17	18	19	20	21	22	23	24	25	26	27	28	29	30	31	
				Lot No.:	201191817	201191818	201191819	201191820	201191821	201191822	201191823	201191824	201191825	201191826	201191827	201191828	201191829	201191830	201191831
	IHWC cell line	A*	A*																
1	9001 SA	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
2	9280 LK707	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
3	9011 E4181324	*01:01		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
4	9275 GU373	*30:01		-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
5	9009 KAS011	*01:01		-	-	-	-	-	-	-	-	-	-	+	-	-	-	-	
6	9353 SM	*02:01	*26:03	-	-	-	-	-	-	-	+	-	-	-	-	+	+	-	
7	9020 QBL	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	
8	9025 DEU	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
9	9026 YAR	*26:01		-	-	-	-	-	-	-	-	-	-	-	-	-	+	-	
10	9107 LKT3	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
11	9051 PITOUT	*29:02		-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
12	9052 DBB	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
13	9004 JESTHOM	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
14	9071 OLGA	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
15	9075 DKB	*24:02		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
16	9037 SWEIG007	*29:02		-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
17	9282 CTM3953540	*03:01	*80:01	-	-	-	-	-	-	-	+	-	-	+	+	-	-	-	
18	9257 32367	*33:03	*74:01	-	+	+	-	-	-	-	-	-	+	-	-	-	-	-	
19	9038 BM16	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
20	9059 SLE005	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
21	9064 AMALA	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
22	9056 KOSE	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
23	9124 IHL	*02:01	*34:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
24	9035 JBUSH	*32:01		+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
25	9049 IBW9	*33:01		-	+	-	-	-	-	-	-	-	+	-	-	-	-	-	
26	9285 WT49	*02:05		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
27	9191 CH1007	*24:10	*29:01	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
28	9320 BEL5GB	*02:01	*29:02	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
29	9050 MOU	*29:02		-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
30	9021 RSH	*30:01	*68:02	-	-	-	+	-	-	-	-	-	+	-	-	+	-	-	
31	9019 DUCAF	*30:02		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
32	9297 HAG	*02:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
33	9098 MT14B	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
34	9104 DHIF	*31:01		-	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
35	9302 SSTO	*32:01		+	-	-	-	-	-	-	-	-	+	-	-	-	-	-	
36	9024 KT17	*02:06	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
37	9065 HHKB	*03:01		-	-	-	-	-	-	-	-	-	-	+	+	-	-	-	
38	9099 LZL	*02:17		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
39	9315 CML	*01:01	*03:01	-	-	-	-	-	-	-	-	-	-	+	+	+	-	-	
40	9134 WHONP199	*02:07	*30:01	-	-	-	-	-	-	-	-	-	+	-	-	+	-	-	
41	9055 H0301	*03:01		-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	
42	9066 TAB089	*02:07		-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
43	9076 T7526	*02:06	*02:07	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
44	9057 TEM	*66:01		-	-	-	-	-	-	-	-	-	-	-	-	-	-	+	
45	9239 SHJO	*23:01	*24:02	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	
46	9013 SCHU	*03:01		-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	
47	9045 TUBO	*02:16	*03:01	-	-	-	-	-	-	-	-	-	-	-	+	+	-	-	
48	9303 TER-ND	*02:01	*11:01	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	

101.401.48/12 – including *Taq* pol., IFU-01  
 101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
 “Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

## CERTIFICATE OF ANALYSIS

### Olerup SSP® HLA-A low resolution

**Product number:** 101.401-48/12 – including *Taq* polymerase  
 101.401-48u/12u – without *Taq* polymerase  
**Lot number:** 02N  
**Expiry date:** 2014-April-01  
**Number of tests:** 48 tests – Product No. 101.401-48/48u  
 12 tests – Product No. 101.401-12/12u  
**Number of wells per test:** 31 + 1

### Well specifications:

Well No.	Production No.	Well No.	Production No.	Well No.	Production No.
1	2011-918-01	13	2011-918-13	25	2011-918-25
2	2011-918-02	14	2011-918-14	26	2011-918-26
3	2011-918-03	15	2011-918-15	27	2011-918-27
4	2011-918-04	16	2011-918-16	28	2011-918-28
5	2011-918-05	17	2011-918-17	29	2011-918-29
6	2011-918-06	18	2011-918-18	30	2011-918-30
7	2011-918-07	19	2011-918-19	31	2011-918-31
8	2011-918-08	20	2011-918-20		
9	2011-918-09	21	2011-918-21		
10	2011-918-10	22	2011-918-22		
11	2011-918-11	23	2011-918-23		
12	2011-918-12	24	2011-918-24		

The specificity of each primer solution of the kit has been tested against 48 well characterized IHWC cell line DNAs.

Additional 5'- and 3'-primers in primer solutions 4, 5, 7, 8, 12, 14 to 17, 20 to 23 and 26 were tested by separately adding 3'-primers, respectively 5'-primers. One additional 5'-primer in primer solutions 1 and 10 was tested by separately adding one 3'-primer. Additional 3'-primers in primer solutions 6, 18, 19 and 27 were tested by separately adding one 5'-primer. One or two of the 5'-primers in primer solutions 2, 9 to 11, 15 and 29 were not possible to test, and in primer solutions 3, 8, 18 and 19 one 3'-primer was not possible to test.

The negative control primer pairs, **Production No. 2011-928-01**, can detect contamination with PCR products diluted  $10^{-7}$ .

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

**Results:** No false positive or false negative amplifications were obtained.

**Date of approval:** 2012-February-21

**Approved by:**

**Production Quality Control**

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

## Declaration of Conformity

**Product name:** *Olerup* SSP® HLA-A low resolution  
**Product number:** 101.401-48/48u, -12/12u  
**Lot number:** 02N

**Intended use:** HLA-A low resolution histocompatibility testing

**Manufacturer:** *Olerup* SSP AB  
Franzengatan 5  
SE-112 51 Stockholm, Sweden  
**Phone:** +46-8-717 88 27  
**Fax:** +46-8-717 88 18

We, *Olerup* SSP AB, hereby declare that this product, to which this Declaration of Conformity relates is in conformity with the following Standard(s) and other normative document(s) ISO 9001:2008 and ISO 13485:2003, following the provisions of the 98/79/EC Directive on *in vitro* diagnostic medical devices, Annex II List B, conformity assessed using Annex IV, as transposed into the national laws of the Member States of the European Union.

The Technical Documentation File is maintained at *Olerup* SSP AB, Franzengatan 5, SE-112 51 Stockholm, Sweden.

Notified Body: Lloyd's Register Quality Assurance Limited, Hiramford, Middlemarch Office Village, Siskin Drive, Coventry CV3 4FJ, United Kingdom. (Notified Body number: 0088.)

Stockholm, Sweden  
2012-July-20

Ann-Cathrin Jareman  
Head of QA and Regulatory Affairs

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

101.401.48/12 – including *Taq* pol., IFU-01  
101.401.48u/12u – without *Taq* pol., IFU-02

Visit [www.olerup-ssp.com](http://www.olerup-ssp.com) for  
“Instructions for Use” (IFU)

Lot No.: **02N**

Lot-specific information

**ADDRESSES:**

**Manufacturer:**

**Olerup SSP AB**, Franzengatan 5, SE-112 51 Stockholm, Sweden.

**Tel:** +46-8-717 88 27

**Fax:** +46-8-717 88 18

**E-mail:** [info-ssp@olerup.com](mailto:info-ssp@olerup.com)

**Web page:** <http://www.olerup-ssp.com>

**Distributed by:**

**Olerup GmbH**, Löwengasse 47 / 6, AT-1030 Vienna, Austria.

**Tel:** +43-1-710 15 00

**Fax:** +43-1-710 15 00 10

**E-mail:** [support-at@olerup.com](mailto:support-at@olerup.com)

**Web page:** <http://www.olerup.com>

**Olerup Inc.**, 901 S. Bolmar St., Suite R, West Chester, PA 19382

**Tel:** 1-877-OLERUP1

**Fax:** 610-344-7989

**E-mail:** [info.us@olerup.com](mailto:info.us@olerup.com)

**Web page:** <http://www.olerup.com>

For information on *Olerup* SSP distributors worldwide, contact **Olerup GmbH**.